Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Beijing Konruns Pharmaceutical Co's Net Margin % or its related term are showing as below:
SHSE:603590'
s Net Margin % Range Over the Past 10 Years
Min: 5.11 Med: 20.47 Max: 81.08
Current: 18.38
SHSE:603590's Net Margin % is ranked better than 86.21% of 943
companies
in the Biotechnology industry
Industry Median: -89.56
vs SHSE:603590: 18.38
Beijing Konruns Pharmaceutical Co (SHSE:603590) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Beijing Konruns Pharmaceutical Co Net Margin % Related Terms
Beijing Konruns Pharmaceutical Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Konruns Pharmaceutical Co Net Margin % Chart
SHSE:603590 vs VRTX, REGN, RVMD: Net Margin % Comparison
For the Biotechnology subindustry, Beijing Konruns Pharmaceutical Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Konruns Pharmaceutical Co Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beijing Konruns Pharmaceutical Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Beijing Konruns Pharmaceutical Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Konruns Pharmaceutical Co (SHSE:603590) has a Net Margin % of 21.97% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Beijing Konruns Pharmaceutical Co and its competitors. This is near median its historical median of 20.47. Over the past decade, Beijing Konruns Pharmaceutical Co's Net Margin % has ranged from 5.11 to 81.08. According to the industry distribution chart, Beijing Konruns Pharmaceutical Co ranks #130 out of 943 companies in the Biotechnology industry, placing it in the top 13.8%.
Is Beijing Konruns Pharmaceutical Co's Net Margin % too high?
Beijing Konruns Pharmaceutical Co's current Net Margin % of 21.97% is near median its 10-year median of 20.47. Over the past 10 years, this metric has ranged from a low of 5.11 to a high of 81.08. Based on the distribution chart, Beijing Konruns Pharmaceutical Co ranks #130 out of 943 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Beijing Konruns Pharmaceutical Co has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Konruns Pharmaceutical Co's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Konruns Pharmaceutical Co ranks #130 out of 943 companies for Net Margin %. This places Beijing Konruns Pharmaceutical Co in the top 14% of its industry — outperforming the majority of peers. Historically, Beijing Konruns Pharmaceutical Co's own Net Margin % has ranged from 5.11 to 81.08 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Beijing Konruns Pharmaceutical Co and its competitors. Beijing Konruns Pharmaceutical Co's current Net Margin % is 21.97%, which is near median its own 10-year median of 20.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Konruns Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Konruns Pharmaceutical Co (SHSE:603590) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥35.27, compared to a current price of ¥29.50 — trading 16.4% below its estimated fair value. The current Net Margin % is 21.97%, which is near median its 10-year median of 20.47. Beijing Konruns Pharmaceutical Co's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Beijing Konruns Pharmaceutical Co (SHSE:603590), the current Net Margin % is 21.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Konruns Pharmaceutical Co (SHSE:603590) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Konruns Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥29.50 is trading 16.4% below its estimated GF Value™ of ¥35.27.
GuruFocus considers Beijing Konruns Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:603590:
Net Margin %: 21.97% (near median its 10-year median of 20.47)
GF Value™: ¥35.27 vs. price of ¥29.50 (16.4% below fair value)
No single metric tells the full story. See the SHSE:603590 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Konruns Pharmaceutical Co Business Description
Beijing Konruns Pharmaceutical Co Ltd is a Chinese pharmaceutical company. It is engaged in the research and development of inventive drugs, and is oriented to clinical needs.
79GF Score
Get the complete analysis for SHSE:603590
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603590 has been successfully added to your 
